Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

tudy of Voreloxin and Cytarabine Indicates Activity of Combination Regimen

Preliminary results were also presented today from Sunesis' ongoing dose-escalating Phase 1b clinical trial evaluating voreloxin in combination with cytarabine, the current standard of care in patients with relapsed and/or refractory AML. The Phase 1b trial is designed to evaluate the safety and tolerability, and to provide a preliminary assessment of anti-leukemic activity, of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days. Of twelve evaluable patients in the first three cohorts, three patients have achieved CRs (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin), and no dose limiting toxicities have been observed thus far at this dose. Patients are now being enrolled in cohort 5 at 70 mg/m2 of voreloxin. Voreloxin pharmacokinetics have so far been unaffected by the combination with cytarabine.

"We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting results from this study later in the year, including CR rates at 50 mg/m2 and higher dose levels of voreloxin," continued Dr. Michelson.

These data were presented today in a poster titled "Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients >/= 60 Years Old Compared to <60 Years Old: Results of a Phase 1b Study" (Abstract #0515) at the 13th Congress of the European Hematology Association. A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally re
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
(Date:7/13/2014)... 2014 According to the Living With ... a comprehensive guide that features a series of tips ... (keratosis pilaris). This guide consists of 14 chapters ... Pilaris? ,     Chapter 2: What Cause KP? , ... Have KP? ,     Chapter 4: Keratosis Pilaris Treatment ...
(Date:7/12/2014)... NY (PRWEB) July 12, 2014 The ... growth over the past five years, buoyed by stable ... sector's supply management system. “Eggs are a relatively affordable ... per capita egg consumption generally grows in line with ... Analyst Will McKitterick. Furthermore, demand for new specialty egg ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... 12, 2014 The fastest-growing mobile technology ... and measurement of LTE networks continues to grow due ... smart devices have increased mobile data traffic, which is ... (CT&M) market. Communications Test and Measurement equipment comply with ... The Communications Test and Measurement Market is estimated to ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5
... and servants, but Maya commoners found a way to record ... A new study of the objects embedded in the floors ... Belize begins to decode their story. The study, from ... the Journal of Social Archaeology . Maya in ...
... ... website that will help people live a healthy life, offering all-natural, American-made, high-purity supplements. ... (PRWEB) April ... Ophthalmology and the American Board of Environmental Medicine. Along with his many years in ...
... a person contributes to a social network site, the more ... News) -- The secret to online popularity lies in the ... , In a new study, British investigators analyzed the activity ... post entries about their daily lives. The study authors found ...
... ... is responding to a magnitude 6.9 earthquake that has rocked Western China. , ... Lakewood Ranch, FL (Vocus) ... 6.9 earthquake that has rocked Western China., , , , ,The earthquake struck the ...
... free health care worldwide through his nonprofit organization Remote ... as the recipient of the 2010 Inamori Ethics Prize, ... Excellence at Case Western Reserve University. Brock, ... other health care professionals to provide free medical services ...
... on hormone therapy, study found , WEDNESDAY, April 14 ... greater risk for developing blood clots, especially if they,re ... indicate that it is important to consider thromboembolic [blood-clotting] ... those who require endocrine treatment," said Mieke van Hemelrijck, ...
Cached Medicine News:Health News:Classic Maya history is embedded in commoners' homes 2Health News:Classic Maya history is embedded in commoners' homes 3Health News:Enviro-Med -- The New Solution to a Healthier Life 2Health News:Enviro-Med -- The New Solution to a Healthier Life 3Health News:ShelterBox Responds to Earthquake in Western China 2Health News:RAM founder to receive CWRU's Inamori Ethics Prize 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 3
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: